3 results
The primary study objective is to assess the proportion of patients who remain within the IGF-I age adjusted normal limits with pasireotide LAR (60 mg) monotherapy, after 24 weeks of treatment.Secondary study objectives are assessment of the…
Primary Study Objective:To assess the efficacy and safety of the co-administration of low-dose pegvisomant (40 mg, administered via subcutaneous injection given once a week) and long-acting somatostatin analogs (administered once monthly) on the…
The purpose of this research study is to evaluate the safety and tolerability of two study vaccines, ACI-35.030 and JACI-35.054 in subjects with a mild form of Alzheimer*s disease who are 50-75 years-old. Both study vaccines have been designed to…